Of note, GPRC5A in primary tumors was inversely correlated with the reduction in tumor burden at the end of treatments, defined by the objective response rate (ORR), and with platinum sensitivity, considering sole administration or combination with taxane (Fig 9E, Appendix Table S7; P = 0.034 and 0.011). The gene discussed is GPRC5A; the disease is neoplasm.